References
- 1.
NIH National Library of Medicine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012 [displayed 15 February 2024]. Available at
https://www.ncbi.nlm.nih.gov/books/NBK547852/ NIH National Library of Medicine LiverTox: Clinical and Research Information on Drug-Induced Liver Injury Bethesda (MD) National Institute of Diabetes and Digestive and Kidney Diseases 2012 [displayed 15 February 2024]. Available athttps://www.ncbi.nlm.nih.gov/books/NBK547852/ - David S, Hamilton JP. Drug-induced liver injury. US Gastroenterol Hepatol Rev 2010;6:73–80. PMCID: PMC3160634
- Abdel-Moneim SM, Sliem H. Significance of serum alpha-glutathione S-transferase assessment in hepatitis C patients with different alanine aminotransferase patterns. Gastroenterology Res 2011;4:13–9. doi: 10.4021/gr269w
- Giffen PS, Pick CR, Price MA, Williams A, York MJ. Alpha-glutathione S-transferase in the assessment of hepatotoxicity - its diagnostic utility in comparison with other recognized markers in the Wistar Han rat. Toxicol Pathol 2002;30:365–72. doi: 10.1080/01926230252929945
- Maina I, Rule JA, Wians FH, Poirier M, Grant L, Lee WM. α-glutathione S-transferase: a new biomarker for liver injury? J Appl Lab Med 2016;1:119–28. doi: 10.1373/jalm.2016.020412
- Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI. Drug-induced liver injury: Interactions between drug properties and host factors. J Hepatol 2015;63:503–14. doi: 10.1016/j.jhep.2015.04.016
- Zhou Y, Wang J, Zhang D, Liu J, Wu Q, Chen J, Tan P, Xing B, Han Y, Zhang P, Xiao X, Pei J. Mechanism of drug-induced liver injury and hepatoprotective effects of natural drugs. Chin Med 2021;16(1):135. doi: 10.1186/s13020-021-00543-x
- Prysyazhnyuk V, Sydorchuk L, Sydorchuk R, Prysiazhniuk I, Bobkovych K, Buzdugan I, Dzuryak V, Prysyazhnyuk P. Glutathione-S-transferases genes-promising predictors of hepatic dysfunction. World J Hepatol 2021;13:620–33. doi: 10.4254/wjh.v13.i6.620
- Chanhom N, Wattanapokayakit S, Satproedprai N, Suvichapanich S, Mahasirimongkol S, Chaikledkaew U, Udomsinprasert W, Mushiroda T, Jittikoon J. CYP2E1, GSTM1, and GSTT1 genetic polymorphisms and their associations with susceptibility to antituberculosis drug-induced liver injury in Thai tuberculosis patients. Heliyon 2021;7:e06852. doi: 10.1016/j.heliyon.2021.e06852
- Lucena MI, Andrade RJ, Martínez C, Ulzurrun E, García-Martín E, Borraz Y, Fernández MC, Romero-Gomez M, Castiella A, Planas R, Costa J, Anzola S, Agúndez JAG. Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008;48:588–96. doi: 10.1002/hep.22370
- Gawryluk JW, Wang JF, Andreazza AC, Shao L, Yatham LN, Young LT. Prefrontal cortex glutathione S-transferase levels in patients with bipolar disorder, major depression and schizophrenia. Int J Neuropsychopharmacol 2011;14:1069–74. doi: 10.1017/S1461145711000617
- Fu S, Wu D, Jiang W, Li J, Long J, Jia C, Zhou T. Molecular biomarkers in drug-induced liver injury: challenges and future perspectives. Front Pharmacol 2020;10:1667. doi: 10.3389/fphar.2019.01667
- Karahalil B, Engin AB, Coşkun E. Could 8-oxoguanine DNA glycosylase 1 Ser326Cys polymorphism be a biomarker of susceptibility in cancer? Toxicol Ind Health 2014;30:814–25. doi: 10.1177/0748233712463777
- Pinheiro DS, Santos RDS, de Brito RB, Cruz AHDs, Ghedini PC, Reis AAS. GSTM1/GSTT1 double-null genotype increases risk of treatment-resistant schizophrenia: A genetic association study in Brazilian patients. PLoS One 2017;12(8):e0183812. doi: 10.1371/journal.pone.0183812
- Kim SK, Kang SW, Chung JH, Park HJ, Cho KB, Park MS. Genetic polymorphisms of glutathione-related enzymes (GSTM1, GSTT1, and GSTP1) and schizophrenia risk: A meta-analysis. Int J Mol Sci 2015;16:19602–11. doi: 10.3390/ijms160819602
- Yan C, Duan L, Fu C, Tian C, Zhang B, Shao X, Zhu G. Association between glutathione S-sransferase (GST) polymorphisms and schizophrenia in a Chinese Han population. Neuropsych Dis Treat 2020;16:479–87. doi: 10.2147/NDT.S235043
- Sakata S, Shinkai T. A functional polymorphism (Ser326Cys) of the human 8-oxoguanine DNA glycosylase (hOGG1) gene and schizophrenia. Psychiat Res 2010;177:268–9. doi: 10.1016/j.psychres.2010.02.007
- 18.
American Psychiatric Association. Diagnostic and Statistical Manual of mental Disorders. 4th ed. Washington (DC): American Psychiatric Publishing, Inc.; 1994 [displayed 15 February 2024]. Available at
https://img3.reoveme.com/m/2ab8dabd068b16a5.pdf American Psychiatric Association Diagnostic and Statistical Manual of mental Disorders 4th ed Washington (DC) American Psychiatric Publishing, Inc. 1994 [displayed 15 February 2024]. Available athttps://img3.reoveme.com/m/2ab8dabd068b16a5.pdf - Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, Glikman J, Januel D. Tolérance hépatique des antipsychotiques atypiques [Hepatic tolerance of atypical antipsychotic drugs, in French]. Encephale 2002;28(6 Pt 1):542–51. PMID: 12506267
- Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1255–60. doi: 10.1016/j.pnpbp.2007.05.005
- Karahalil B, Kocabaş NA. hOGG1 SER326CYS genetic polymorphism in a Turkish population. Arch Toxicol 2005;79:377–80. doi: 10.1007/s00204-005-0665-5
- Gönül N, Kadioglu E, Kocabaş NA, Ozkaya M, Karakaya AE, Karahalil B. The role of GSTM1, GSTT1, GSTP1, and OGG1 polymorphisms in type 2 diabetes mellitus risk: A case-control study in a Turkish population. Gene 2012;505:121–7. doi: 10.1016/j.gene.2012.05.025
- Uřinovská R, Brozmanová H, Sištík P, Silhán P, Kacířová I, Lemr K, Grundmann M. Liquid chromatography-tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2012;907:101–7. doi: 10.1016/j.jchromb.2012.09.009
- Karahalil B, Elkama A, Ak M, Nemutlu E. Metabolomics mapping changed after olanzapine therapy in drug-naive schizophrenia patients-the significant impact of gene polymorphisms. Toxicol Res (Camb) 2022;11:547–56. doi: 10.1093/toxres/tfac034
- Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175–91. doi: 10.3758/BF03193146
- Czuczejko J, Mila-Kierzenkowska C, Szewczyk-Golec K. Plasma α-glutathione S-transferase evaluation in patients with acute and chronic liver injury. Can J Gastroenterol Hepatol 2019;2019:5850787. doi: 10.1155/2019/5850787
- Kolpe M, Ravasia S. Effect of olanzapine on the liver transaminases. Can J Psychiatry 2003;48(3):210. doi: 10.1177/070674370304800313
- Lui SY, Tso S, Lam M, Cheung EF. Possible olanzapine-induced hepatotoxicity in a young Chinese patient. Hong Kong Med J 2009;15:394–6. PMID: 19801701
- Ciba M, Ak M, Karahalil B. Alpha-glutathione-s-transferase can be a biomarker for both drug-related toxicity as well as individual susceptibility. Minerva Psichiatrica 2016;57:62–71.
- Manceaux P, Constant E, Zdanowicz N, Jacques D, Reynaert C. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature. Psychiatr Danub 2011;23(Suppl 1):S15–7. PMID: 21894094
- Ozcanli T, Erdogan A, Ozdemir S, Onen B, Ozmen M, Doksat K, Sonsuz A. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1163–6. doi: 10.1016/j.pnpbp.2006.03.014
- Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, Kowatch R, Wagner K, Findling R, Lin D, Robertson-Plouch C, Xu W, Dittmann RW, Biederman J. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 2007;164:1547–56. doi: 10.1176/appi.ajp.2007.06111932